May 3, 2024 · SGT-53 is under development for the treatment of metastatic pancreatic cancer (pancreatic adenocarcinoma), triple-negative breast cancer (TNBC), ...
Missing: q= https://
People also ask
What is the #1 cause of pancreatic cancer?
How quickly do you deteriorate with pancreatic cancer?
Where is the first place pancreatic cancer spreads?
How long does it take to go from stage 1 pancreatic cancer to stage 4?
Study of p53 targeting molecule, SynerGene Therapeutics 53 (SGT-53), is being currently tested in combination with nab-paclitaxel/gemcitabine ({"type ...
Missing: url? likelihood-
Apr 19, 2024 · GlobalData's report assesses how Nivolumab's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.
Missing: synergene/ q= https:// sgt- 53- synergene-
May 8, 2014 · (30) The FDA has also approved a phase Ib/II trial of SGT-53 in combination with gemcitabine for treatment of pancreatic cancer. Moreover ...
Given the limited and mainly chemotherapy-based treatment options available, their suboptimal therapeutic efficacy, and the persistently poor outcomes observed ...
Aug 31, 2021 · This paper will review the landscape of pancreatic cancers, focusing on mutations of p53, a major tumor suppressor protein, in pancreatic ...
Missing: synergene/ technology. insights/ sgt- synergene- approval/
... tumors while reducing immune-related adverse events. Our data suggest that SGT-53, representing tumor-targeted TP53 gene therapy, has potential to augment ...
Recently, a fluorouracil and leucovorin combination therapy-based product was approved for metastatic adenocarcinoma of the pancreas. This product is marketed ...
Jan 2, 2023 · DelveInsight's pancreatic cancer pipeline report depicts a robust space with 150+ active players working to develop 170+ pipeline therapies for ...
Mar 23, 2024 · We specifically focus on the TME and epigenetic-targeted therapies in the context of PDAC, discussing the advantages and limitations of current ...